FIXX News and Press, Homology Medicines Inc. From 01/28/20

Genetic medicines and cellular therapies have an enormous potential to treat, and possibly cure, currently untreatable diseases. Nonetheless, it's important for investors to remember that "simpler" treatment options won't become obsolete just because gene therapy, gene editing, and immunotherapy...

The long awaited pheNIX Phase 1/2 first human data for Phenylketonuria (PKU) was finally released after the close December 17. (press release link) (slide show link) While appearing to show safety, Cohort 1 of two patients showed no efficacy at the low dose. Cohort 2 of n=2 (but only r...

Gainers: ASLN   +8.6% . NK   +7.1% . SCS   +5.5% . OBSV   +2.8% . CTAS   +2.8% . More news on: ASLAN Pharmaceuticals Limited, NantKwest, Inc., Steelcase Inc., Stocks on the move, , News on ETFs Read more ...

Preliminary data from a Phase 1/2 clinical trial, pheNIX , evaluating Homology Medicines' (NASDAQ: FIXX ) gene therapy HMI-102 in patients with phenylketonuria (PKU) showed encouraging action. More news on: Homology Medicines, Inc., Synlogic, Inc., BioMarin Pharmaceutical Inc., Healthc...

- Well-Tolerated in First-in-Human AAVHSC Gene Therapy Trial - - Preliminary Data from First Patient in Second Cohort Showed Dose-Response with Observed Reductions from Baseline in Phe and Phe/Tyr Ratio and Increased Tyr - - Conference Call/Webcast at 4:30 p.m. ET Today, Dece...

These Data Highlight Unmet Medical Need for Therapies to Control Phe Concentrations by Targeting the Underlying Cause of PKU BEDFORD, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publicat...

- Experienced Clinical Geneticist with Track Record in Rare Disease Drug Development Joins Homology’s Senior Management -  BEDFORD, Mass., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has ...

BEDFORD, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its proprietary adeno-associated viral vectors (AAVHSCs) crossed the blood-brain-barrier and blood-nerve-barrier ...

Homology Medicines (NASDAQ: FIXX ): Q3 GAAP EPS of -$0.67 misses by $0.07 . More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Expects to Report Initial Clinical Data from Phase 1/2 pheNIX PKU Gene Therapy Clinical Trial by Year-End Presented Preclinical Data Demonstrating Progress in MLD Gene Therapy and PKU Gene Editing Programs BEDFORD, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc...